Notably, in ovarian cancer cells, BPA activates the PI3K/Akt signaling pathway; analogues such as BPS and BPF display comparable estrogenic potency, while BPAF often exceeds BPA in ERα activation, suggesting their potential oncogenicity. This evidence concerns the gene AKT1 and ovarian cancer.